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2Abstract:
Introduction: Rare paediatric diseases are clinically severe with high rates of mortality and morbidity.
This review outlines how Next Generation Sequencing (NGS)can be used to greatly advance the
identification of the underlying genetic causes.
Areas Covered: This review is a blend of evidence obtained from literature searches from
PubMed and rare disease related websites, laboratory experience and the author’s
opinions. The review covers the current state of the field and identifies where the challenges lie and
how they are being overcome, using up-to-date references.
Expert Opinion: The field of NGS is still relatively new but it has already transformed the field of rare
disease research. Technological advances in instrumentation and computational hardware and
software have resulted in the identification of many causative genes but as sequencing moves into
population-scale initiatives standardisation and data sharing is going to be paramount to ensure we













1.1. The challenges of diagnosing rare paediatric diseases:
Rare diseases are typically severe, genetic in origin and in the vast majority of cases affect children.
In Europe a rare disease (RD), as defined by the European Commission, is one that occurs in less than
1 in 2,000 individuals. The total number of RDs that fall within this definition is difficult to determine
exactly but best estimates put number at over 7000 [1]. One reason for this uncertainty is that
current nosology uses umbrella terms such as intellectual disability to aggregate samples that
probably have multiple and distinct aetiological routes to causation and thus leads to an
underestimate of the true diversity of diseases. Another reason is that due to their individual rarity
not all rare diseases have yet been documented and those that have are typically derived from
developed regions with good healthcare provision suggesting that many more diseases are currently
unreported due to a lack of healthcare in undeveloped regions of the world. What’s more, given that
the majority of human genes show high conservation across the mammalian lineage, it is probable
that specific mutations in a large proportion of all human genes will result in a phenotypic outcome
[2]. This will probably also be the case for a subset of the less-conserved genes that mark inter-
species differences. Current observations, with mutations in over 2,900 human genes already
characterised [3-5] and an increasing number of novel disease genes being published weekly, lends
credence to this view.
Collectively RDs pose a significant psychological burden [6] to patients and their families and a
significant financial burden to the healthcare system. The psychological burden comes from the
4obvious emotions associated with having or caring for someone with a RD but is amplified by the
observation that as many as 75% of RDs have their onset at birth or in childhood and that 15% of
affected children will not live beyond 5 years of age. The financial burden to the healthcare system
comes from the fact that in aggregate RDs affect around 1 in 17 of the population, which in the UK
which equates to 3.5 million people (www.raredisease.org.uk). Moreover, the typically early age of
onset for RDs results in a substantial lifelong burden of disability which has been estimated to cost in
the region of €2,000,000 per patient [7]. This high cost results, in part, from our lack of
understanding of the pathobiological aetiology of most RDs, leading to a dearth of specific therapies.
This leads to a situation whereby clinical treatments are focused on ameliorating the key symptoms
rather than targeting the underlying pathobiology.
To help reduce the psychological and financial burden associated with RDs we need to be able to
make a rapid and accurate diagnoses and, when a diagnosis is made, we need to have targeted
therapies available to treat or alleviate the symptoms. Currently however, the causative gene has
been identified in less than half of all known RDs, meaning there are still over 3,500 diseases where
no gene has yet been discovered. Furthermore, for many RDs where known genes have been
identified, only a subset of patients will have mutations within these genes meaning that, even for
the 3,500 RDs where genes have been identified, there are still a substantial number of patients
diagnosed with a RD but without a genetic diagnosis.
There is a specific group of RD patients for whom obtaining a diagnosis is even more difficult. These
are the uncharacterised disease patients, who have an array of phenotypic features that make them
unique and unlike any known documented RD. For these patients getting a diagnosis usually only
comes through the identification of other phenotypically identical patients and the identification of a
novel causative gene [8]. As these patients tend to be the ‘rarest of the rare’ finding matching
patients is not always possible and so many of them have to live without a definitive diagnosis and
with an unknown prognosis. For RD patients the term ‘diagnostic odyssey’ is well known and
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been shown that the average rare disease patient will consult with 5 doctors, receive 3 misdiagnoses
and wait 4 years until they get the correct diagnosis (www.raredisease.org.uk). For families,
receiving the correct diagnosis is important because without it patients find it difficult to access the
correct specialists and receive appropriate therapies, which can result in un-necessary patient
suffering. Furthermore, delayed treatment can result in continued pathology that will increase their
long-term morbidity and suffering. The psychological burden can also be increased in patients
without a diagnosis as there is the constant uncertainty as to the future prognosis. To help RD
patients and their families there are a large number of patient groups and charities (e.g. Rare
Disease UK) that give patients and their families access to help, advice and support which many find
invaluable. These networks are able to lobby on behalf of RD patients and their families and have led
to many changes in government and in health authorities to raise the awareness of RDs and to
improve patient treatment. An example of this comes from the work of the charity Rare Diseases UK
that has resulted in a unified Implementation Strategy for Rare Diseases in the UK
(www.raredisease.org.uk), this is a document listing specific targets the devolved health authorities
across the UK should adhere to so as to ensure continuity of treatment. For patients without a
diagnosis it can be difficult to obtain similar support as many of these charities are dedicated
towards a single or group of related RDs, however there are some notable exceptions
(UNIQUE:www.rarechromo.co.uk and SWAN: undiagnosed.org.uk) that bring together patients
without a diagnosis so that they can share experiences and help to support each other.
One of the key challenges of diagnosing patients with RDs comes from the way in which a diagnosis
is typically made. To make a diagnosis the reviewing clinician will assess the patient’s phenotype
which includes the patients’ physical characteristics plus any diagnostic test results, then using their
wealth of clinical knowledge make a subjective judgement. In many instances this is sufficient to
provide a definitive diagnosis, especially where the phenotypic or diagnostic test data is striking and
defines an obvious RD. However, the sheer number of RDs combined with the fact that many are so
6rare that a clinician will be unlikely to have ever personally seen another patient means it is not
always so simple.
It is also worth remembering that each individual is unique and their phenotype results from the
complex interplay between their genetic background and environmental influences. This can give
rise to the phenomenon referred to as phenotypic heterogeneity, that is, where a group of patients
with mutations in the same RD gene display a spectrum of phenotypes some of which do not overlap
and others that may overlap with other RDs [9] or locus heterogeneity where patients with the same
RD phenotype have mutations in different genes [10] and incomplete penetrance, where individuals
with known disease causing alleles do not display a disease phenotype [11]. A further complication
in diagnosis comes with the diagnoses of very young children and babies as their phenotype can
commonly look different to that of older children and adults, resulting in their RD as not being
recognised.
It has been estimated that in a standard clinical setting the success in diagnosing RD patients can
range from approximately 50% [1,12] to as low as 34% (11% in children) [13]. Indeed, within our own
group GOSgene, that focuses on the diagnosis of children with rare undiagnosed diseases we too
have achieved a diagnostic rate of ~45% (unpublished findings). Therefore, more than half of all
patients with a RD fail to obtain a diagnosis which represents a huge unmet need and is a major
challenge for clinical genetics to overcome.
1.2. How to overcome these challenges:
Firstly, it should be recognised that the achievements to date in the field of RD research have been
outstanding. That we are able to diagnose almost half of all patients with a RD is the result of many
decades worth of endeavour by scientists and clinicians, many of whom have focused their careers
towards elucidating the cause and treatments for specific RDs. Through the identification of specific
mutations that link genetic variation to altered protein function/dynamics and observable
phenotypes we have been able to progress our understanding of a human development and
7physiology in both health and disease. Moreover, in many ways the identification of mutations in RD
research has been the driving force in understanding the link between gene function and phenotype
diversity in humans. By finding out what has gone wrong we have been able to elucidate biological
systems previously unknown.
1.3. Technological innervation:
A major turning point in RD research came in 2009 with the publication of the first manuscript that
described the use of NGS for the identification of RD genes [14]. The NGS technique employed in this
study was that of Whole Exome Sequencing (WES). This technique involves the use of a hybridisation
step that uses baits that are targeted specifically to the coding 1-2% of the human genome (the
exons). By targeting just the exonic region of the genome researchers are able to sequence only
these regions at a higher coverage and/or more samples to be combined and sequenced together.
This is a far more cost effective method compared to that performing Whole Genome Sequencing
(WGS) which was still prohibitively expensive at that time. Also, there was a sound scientific
rationale for focusing on coding regions as studies to date, including those following up on linkage
signlas, have shown that ~80% of all RD mutations identified have resided within this coding
sequence [15]. A technical description of the different NGS techniques and their evolution is beyond
the scope of this manuscript but readers are encouraged to read the recent review by Goodwin and
colleagues that presents a comprehensive overview [16]. The study by Ng and colleagues
demonstrated the proof-of-concept of using WES as a cost effective technique for gene
identification through the elucidation of candidate genes for Freeman-Sheldon syndrome (FSS) in 4
unrelated affected individuals and in the process also demonstrated the utility of having data from
unaffected control individuals to help filter and prioritise candidate variants [14].
1.4. Sharing is good:
Since the publication of the first WES study to identify a RD mutation the number of studies and RD
genes identified has increased to the point where every week a number of novel RD gene
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price of NGS and the concomitant realisation of groups around the world that NGS is becoming a
cost effective diagnostic tool for RD gene identification [1,2,12,13,17-30]. The widespread use of
NGS has led to the formation of large programs, such as Finding of Rare Disease Genes(FORGE) [1] or
Deciphering Developmental Disorders (DDD) [31], that aim to collaborate together and share
information on RD patients, thus overcoming one of the major problems associated with analysing
NGS data for RD patients, that of having a list of potential causative variants but requiring a second,
phenotypically similar family for confirmation. To aid in the identification of phenotypically similar
patients there is the need to adopt standard phenotypic nomenclature, for example: Human
Phenotype Ontology (HPO) [32] that can be used throughout the RD community to ensure that all
poignant phenotypic features are recorded in an electronic format. Such data can then be used to
search for patients with matching phenotypic overlaps.
Undiagnosed patients still form a substantial fraction of those that have undergone NGS and
strategies need to be put in place to allow for better collaborations to be made. Indeed, there has
been a shift by many groups away from keeping their data locked in silos as they realise that by
sharing their data in a collaborative manner everyone can benefit, especially the patients who may
finally get to receive a diagnosis. This is not trivial task however as the ethics required to share such
information is commonly not available, especially for historical samples, and it also raises pertinent
questions regarding the protection of patient data and that of their families.
The largest such collaborative endeavour, known as the Matchmaker Exchange (MME) [33], acts as a
meta-repository linking various other RD gene identification groups together through an application
programming interface (API). It offers a glimpse into the future of RD research where the
overarching aim is to identify genes for patient benefit through collaboration not isolation. Such
endeavours do however raise pertinent questions that revolve around patient confidentiality and
ethics. To this end MME is working closely with groups such as the Global Alliance for Genomics and
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standards and best practices are maintained.
To help users adhere to local consent agreements for data sharing MME has set up two levels of
matchmaking; Level 1: Requires no additional consent and includes the use of broad phenotype and
HPO terms with candidate gene names (+/- variant type) whereas, Level 2: Requires consent and
included the use of unique or sensitive identifying phenotypic descriptions and sequence level
variant information [34]. By formulating this structure now MME aims to set in place the
foundations of a harmonised system that can be used on a global basis to aid in the sharing of RD
data going into the future.
1.5. Setting the standards now will benefit future studies:
1.5.1. Sequencing hardware:
To share RD variant data globally requires the use of standardised systems to measure, analyse and
annotate the huge amounts of genomic data being produced. None of this work would be possible if
it were not for the Human Genome Project (HGP) [35,36]. Firstly, the HGP gives us a standard
genomic reference that can be referred to and secondly, the technological advances made during its
completion are what led to the development of NGS techniques. It is worth noting that since the
concept of NGS was realised there have been a number of commercial companies employing vastly
different chemistries and technologies to provide high quality, cost effective sequencers. Although
this innovation is still proceeding, albeit in more niche applications, it is obvious that the field of NGS
has become dominated by the use of sequencing machines built by one company, that of Illumina
(www.illumina.com).
1.5.2. Sequencing software:
As the use and diversity of NGS hardware increased so did the number of computational programs
designed to process the data. Unlike the commercial dominance of the NGS hardware market, the
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software market was a free enterprise with the majority of programs being written by research
teams from the academic sector and, as such the majority were open source and free to use. A
downside of open source software is that it can be cumbersome to use, inefficient and highly prone
to crashing due to compatibility bugs. Nonetheless, some of the larger sequencing centres from
around the world have worked to build file formats and analysis tools that are robust and free to use
for academic users and in turn these have been adopted by a significant percentage of NGS users. As
such, the analysis of NGS data is typically performed using the program BWA-MEM [37] to align the
sequence reads to the human reference genome and the software package Genome Analysis Tool
Kit (GATK) [38,39] or SAMtools [40] for variant calling. A typical NGS experiment, utilising the above
hardware and software, will result in a large amount of data for each individual, stored in three
standard file formats; a .fastq file containing the raw sequence data from the sequencing machine, a
.bam file that represents the .fastq data aligned to the human reference genome and a .vcf file that
contains details of just those nucleotides that differ between the individual sequenced and the
reference genome. There are a number of alternative software programs available to map and call
variants that could be included here and the interested reader is advised to refer to relevant
literature such as the comparison by Hwang, S and colleagues to gain more detailed insights [41].
A positive outlook on the consequence arising from the dominance in NGS hardware and software is
that it has given laboratories from across the globe the ability to generate and analyse their data
using a common set of tools that are on the whole compatible. This has allowed large amounts of
data from tens and thousands of samples to be combined while keeping technical artefacts to a
minimum( for example ExAC [42]).
1.5.3. Filtering sequence data:
Once the sequence data for an individual has been generated and processed the next step is to
interpret the findings in an attempt to identify the causative gene. Although there are a myriad of
ways to annotate and analyse the variant data a general workflow is highlighted in figure 1. Briefly,
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the data is first filtered to include only high quality variants (high read depth and call/mapping
quality), that are rare in the general population (<0.5% in ExAC [42] for example) and which are likely
to have a functional impact on a candidate gene (missense, nonsense, frameshift and canonical
splice-site). Familial data can then be used to determine if the candidate variants fit with the
suspected inheritance pattern for that patient (figure 2) and for this step is hugely beneficial to have
sequence data available from both parents (trio), especially for the detection of de novo variants. It
is at this stage at which phenotypic and clinical test data can be incorporated to try to distinguish
between those variants that look potentially damaging but which are in fact benign and those
variants that are causative. As discussed above, this type of gene identification workflow can, at
best, identify causative variants in around half of patients but as the NGS technology improves and
the analysis and interpretation of genome data improves this percentage is set to increase.
1.5.4. The inexorable rise in the use of Whole Genome Sequencing (WGS):
The overwhelming majority of NGS studies in the field of RD gene identification to date have utilised
WES but as the cost of NGS continues to fall it will reach a point where the price differential between
performing WES and WGS becomes negligible. This time is fast approaching and we are soon to
reach the so-called ‘$1000 Genome’, which is predicted to be the time when WGS will be more cost
effective than WES [43]. It is worth at this point considering the advantages and disadvantages of
WGS versus WES, the main points are highlighted in table 1. This demonstrates that although for
most metrics WGS is the better option, the main metric that restricts researchers is the cost, and as
WES is currently cheaper it is, therefore, still the default option for most.
1.6. Factors affecting RD gene identification:
It is worthwhile considering where the potential bottlenecks are likely to be in the gene
identification pathway for RDs. In the first instance, in the pre-NGS era, the technology was the
major barrier, as witnessed by the time and cost of using Sanger sequencing to complete the HGP.
Next, NGS technologies were developed that overcame the limitations of Sanger based sequencing
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but they were initially very expensive, restricting sample numbers. As a consequence targeted
sequencing approaches such as WES were developed as a way to minimise costs and increase usage.
The popularity and success of WES continued to drive innovation in the field of NGS technology,
allowing more data to be produced in shorter time-frames and at lower costs which has led to the
situation now where the price of NGS has reached the point where WGS is sure to become the more
favourable technique soon.
1.6.1. Data storage:
Although NGS has many advantages it can potentially result in a data analysis and storage
bottlenecks due to the increased number of samples that can now be analysed. This is no minor
problem, a typical WES or WGS run will generate 25GB or 75GBof data respectively for a single
sample and, when this is scaled up to include multiple samples it soon becomes too large to be
stored on a standard desktop computer or hard drive. This then requires the use of large
computational servers for the long-term, safe storage of the data which is not trivial and has to be
factored in to the overall cost of an NGS project. More problematic than the storage issue however,
is the processing of the raw (.fastq) data to produce the .bam and .vcf files as the software for this
analysis requires UNIX based operating systems and the use of high performance computing servers
or clusters. For most large academic institutions the high performance computing infrastructures are
in place to allow the simultaneous analysis of a reasonably large set of samples (~30) to be
performed in a timely manner but again the costs associated with the running and maintenance of
such infrastructure has to be factored in to the overall cost of the experiment. Some centres on the
other hand operate on a scale far greater, for example the sequencers at the Broad Institute of MIT
and Harvard generate 20TB of data a day 365 days a year. In an attempt to efficiently handle such
huge amounts of data they are trying innovative ideas and have teamed up with Google Genomics to
develop a cloud based computing solution. The increasing use of high powered computing hardware
and the personnel to run it is minimising the bottleneck surrounding NGS data processing and
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storage but again it is pushing that bottleneck further downstream so that the bottleneck now
becomes the interpretation of the data.
1.6.2. Data Interpretation:
An example of a typical interpretation pipeline for NGS variant data is shown in figure 1.This can be
used for both WES and WGS data and many of the steps can be automated to streamline the
process. The difficulty typically arises when a list of candidate genes remains that fulfil the selection
criteria as these have to be manually assessed on a gene-by-gene basis to determine their role in the
RD being studied. The time taken to complete this process can take anywhere from an hour to days
or weeks even, depending on the amount of follow-up work required. The cost associated with this
level of interpretation can far out way the cost of generating the data, and for diagnostic
laboratories can result in a substantial proportion of their budget, especially when the time taken to
produce a diagnostic report is factored in.
As shown above, the success rate for this type of analysis ranges but at best, in at least half of all
samples no genetic variant will be located. For WES based studies there is little more that can be
done with such data. In comparison, if WGS was performed and no coding variant could be found
then WGS has the major advantage of capturing all the noncoding variation as well as giving far
more robust Copy Number Variant (CNV) data and information relating to Structural Variation (SV)
such as inversions and translocations. This is a vast amount of additional data, for example in our
laboratory, just in terms of variants; WES generates ~50,000 variants whereas WGS generates
~3,500,000 variants and it is the large number of noncoding variants which poses huge problems in
terms of annotation and understanding.
We know from the large number of causative RD variants found to date that they are mostly coding,
rare and loss of function (LOF) and we understand in great detail how changes to the coding
sequence can change protein structure or alter binding characteristics and lead to the phenotypes of
the affected patients. However, when the causative variant is not coding we are suddenly faced with
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whole new set of problems. We can filter our variants by quality (for example, mapping quality) as
the same statistics are relevant but when it comes to filtering by frequency we have a far smaller
dataset that can be used, for example the 1000 Genomes Project [44] data. How we then annotate
the >3,000,000 variants that are noncoding is something that projects such as ENCODE(
Encyclopaedia of DNA Elements) [45] have been striving to answer. The goal of the ENCODE project,
as stated on their website (https://www.encodeproject.org/) is “to build a comprehensive parts list
of functional elements in the human genome, including elements that act at the protein and RNA
levels, and regulatory elements that control cells and circumstances in which a gene is active.” By
using this data we can start to annotate our noncoding variants to see if they reside within a region
of the genome predicted to alter the function of a gene and as we learn more about how to perform
these prioritisations we will become better at identifying candidate genes that we can then apply
our phenotypic knowledge to in order to identify noncoding causative variants for RDs. In practical
terms, the ability to use the ENCODE data in a meaningful way in studies aimed at RD gene
identification is still very much in its infancy and still restricted to research based projects instead of
diagnostic laboratories but it does hold the potential to identify causative regulatory variants we
know exist [46] and it offers much hope that in the future we will be able to identify the cause for
the >50% of RD patients who are refractory to current gene identification studies.
1.7. Future directions:
1.7.1. Population-scale projects:
Although the utilisation of WGS in a systematic way for population-scale RD research projects has
not yet been performed, there are examples of projects that are currently underway that will change
this and which will revolutionise the use of genomics in the healthcare environment. Presently, the
most advanced such project is taking place in the UK, this is the 100,000 Genomes Project (100KGP)
which will perform WGS on 100,000 samples. Of relevance here, half of the genomes sequenced will
be related to RD gene identification and will be achieved through sequencing ~17,000 RD patients
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and their parents in the form of trios, the remaining half of the project will be based on cancer and
infection related studies. The project is funded by the UK government and is being run through the
National Health Service (NHS), thus allowing the electronic Health Records (eHRs) of patients and
their whole-genome data to be combined on a large scale for the first time. One of the aims of the
project is to build the NHS infrastructure that is able to utilise the advances in NGS technology for
patient benefit and to stimulate innovation in the genomic healthcare system by working with
commercial partners and academic groups. A high security computational datacentre has been built
to house all the eHR and genomic data and a number of disease specific clinical/academic
partnerships have been developed to analyse the genomic data of patients that do not receive a
definitive clinical diagnosis following analysis by clinical scientist. By combining the resources of the
NHS with that of academics and commercial partners the 100KGP is likely to have a profound
positive impact on the study of RDs and will no doubt lead to unexpected advances in our
understanding of human genomics.
The 100KGP project has spearheaded a major global shift in the use of WGS for clinical RD research
and already President Barack Obama has set up the personalised medicine initiative in the USA that
plans to perform WGS on 1 million people while Qatar have also launched a population-scale
genomic sequencing project. Sequencing projects on such an unprecedented scale will allow us to
better understand variation across populations, drive innovation and technological advances and;
allow the development of standard methods to analyse, interpret and share data. This latter point is
essential in RD research as there are currently wide discrepancies across diagnostic laboratories in
the interpretation and classification of variants [47] and it will help overcome false positive results
being published on novel variants that are based on allele frequencies derived from inappropriate
populations or insufficient sample sizes [48].
1.7.2. Advanced analytical techniques:
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With access to large homogeneously phenotyped, sequenced and analysed datasets of RD patients
and their families, we will be able to apply higher analytical methods such as those employing bio-
statistical algorithms or machine learning techniques to identify novel variants and better elucidate
the underlying pathobiology. An example of just such an application was demonstrated by Akawi, N
and colleagues who utilised the power of the DDD (Deciphering Developmental Disorders) dataset
by developing a set of statistical tests to identify four novel recessive phenotypes [49]. Other
techniques such as pathway and network analyses hold great promise for the identification of novel
biologically relevant interactomes that can highlight novel biological pathways which could in turn
be targeted by therapeutics [50,51]. In this context, WGS data will allow us to build networks
combining data not only from coding LOF variants but allow us incorporate data from noncoding
regulatory variants that influence both known and novel genes. A consequence of such networks is
that when applied to large well phenotyped datasets they have the potential to delineate
phenotypic subgroups of patients that may be more responsive to a particular drug or therapeutic
intervention.
1.8. The elephant in the room:
The one thing that cannot be ignored when discussing the challenges of RD research is the fact that
usually the singly most difficult part of proving a novel candidate variant is causative is
demonstrating the functionality of the identified variant. There are a suite of prediction programs
and databases that can be interrogated to provide evidence of candidacy but the final test requires
the ability to show in a model system that the identified variant causes a functional effect that
mimics the phenotype seen in the patient. Since the completion of the HGP, the cost and time taken
to perform NGS has fallen to the point now where a whole human genome can be sequenced and
analysed within 26 hours [52] at a cost of a few thousand dollars, whereas the concomitant time and
cost of functionally characterising a candidate variant is still measured in terms of months or even
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years and the cost can easily be in excess of tens of thousands of dollars. To overcome this
bottleneck is going to take huge investment and coordination by laboratories on national and
international scales because as projects such as 100KGP come online there are likely to be hundreds
of novel variants that will need functional validation every month. This is the biggest bottleneck in
translating the results of an NGS experiment into a definitive answer for many patients and although
for many, just receiving a genetic diagnosis is something which is a huge relief, it does not lead to an
improvement in how they are clinically managed or how their symptoms are treated. There have
recently been some major advances in the field of functional biology such as CRISPR/cas9 gene
editing technology and the development of induced pluripotent stem cells (iPSc) reprogramming
techniques that will undoubtedly help expedite the functional characterisation of genetic variants
but the time scales involved are still large.
The reason why it is so important to overcome the bottleneck related to the functional
characterisation of genes is that it provides categorical evidence for the causality of the identified
variant and gives an insight into the underlying pathobiology. Armed with this knowledge it is then
possible to look at therapies that can be used to treat the patients, this may involve relieving the
symptoms or ideally, preventing them from occurring in the first place. This can involve strategies
that use for example; drugs, dietary supplements or gene therapy techniques. The effectiveness of
these interventions however varies widely and therefore many groups are now working on ways to
utilise the genomic knowledge to get a better understanding of the optimal therapeutic strategy on
an individual basis, what is termed personalised medicine.
It should nevertheless be remembered that even with advances in therapeutics, some patients are
going to be refractory to treatment especially if the critical period occurs during development.
1.9. Personalised Medicine:
Personalised medicine has been defined by the US Food and Drug Administration (FDA) as the
tailoring of medical treatment to the individual characteristics, needs and preferences of a patient
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during all stages of care, including prevention, diagnosis, treatment and follow-up
(http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalisedMedicine/UCM37242
1.pdf). The aim is to tailor healthcare to each individual patient or group of patients. The way this is
achieved is by stratifying patients according to their genetic makeup into subgroups with for
example different responses to drugs, different disease risks or other clinically relevant factors. The
stratification results in more cost-effective treatments based on the underlying cause of disease
allowing early intervention in the disease process or preventing the disease from occurring at all.
Patients’ management, surgical interventions and treatments will be informed by variants identified
in their genomes. An example of this is represented by some form of immunodeficiency or very-
early-onset inflammatory bowel disease (VEO-IBD) [53]. By knowing which type of gene or mutation
is responsible for the disease one can inform patient management towards hematopoietic stem cell
transplantation, immunomodulation or gene therapy.
Patients affected by a RD often have few or no drugs available to treat their conditions. In recent
years there has been a shift in the attention of pharmaceutical companies towards RDs drug
development research. This is partly due to the success of the FDA Orphan Drug Designation which
creates incentives and quicker approval process for pharmaceutical companies working on
development of RD drugs. Equally, the advances in genomic research by NGS technologies have
increased the capacity and understanding of diseases. Once the exact causative mutation
responsible for a RD has been identified (i.e. resulting for example in a deficiency or an absence of
an enzyme), the development of a targeted treatment can be easily developed.
Current data from the FDA shows that about 47% of the novel drugs approved in 2015 (21 of 45)
were approved to treat rare or “orphan” diseases. One example is Kanuma (sebelipase alfa)
produced by Alexion Pharmaceuticals Inc., which received Orphan Drug Designation by the FDA for
the treatment of a rare condition known as lysosomal acid lipase (LAL) deficiency [54]. Patients with
LAL deficiency (also known as Wolman disease and cholesteryl ester storage disease [CESD]) have
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little or no LAL enzyme activity resulting in a build-up of fats within the cells of various tissues. This
can lead to liver and cardiovascular disease and other complications. Wolman disease is a
progressive severe disorder that often presents during infancy (around 2 to 4 months of age) and
patients rarely survive beyond the first year of life. Kanuma is a recombinant rhLAL protein that
functions in place of the missing, partially active or inactive LAL protein in the patients and is
administrated intravenously once a week in LAL patients. Other examples are from companies like
Novartis and Genzyme and products for RDs like Gleevec for Chronic Myeloid Leukemia and
Cerezyme for type 1 Gaucher disease.
Great hopes for RDs treatment has also been put into personalised gene therapy. While genomics
studies provide the identification of the genetic defect, gene therapy provides the correction of the
defect. A number of successful trials in the last two decades have employed ex-vivo haematopoietic
stem cell gene therapy as a therapeutic option to treat specific rare inherited immune deficiencies,
including adenosine deaminase deficiency, X-linked severe combined immunodeficiency, chronic
granulomatous disease and Wiskott Aldrich syndrome [55]. In more recent years, other RD patients
have been involved in gene therapy trials for retinitis pigmentosa, X-linked Chronic Granulomatous
Disease, Severe Haemophilia A amongst others. For a complete list of gene therapy trials see
http://www.genetherapynet.com/clinicaltrialsgov.html.
2. Conclusions:
In the field of paediatric Rare Disease (RD) gene discovery there is an optimistic feeling that many of
the obstacles that prevent a diagnosis being made or therapy being found are beginning to be
overcome. It is over a decade since the completion of the Human Genome Project (HGP) [35,36]
which had, as one of its primary aims, the goal of improving of our understanding of human disease.
This objective has been greatly advanced as a direct result of the utilisation of Next Generation
Sequencing (NGS) technologies. NGS has transformed our ability to perform unbiased, genome-wide
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sequencing on large numbers of RD patients and their families and has led to the identification of
the genetic cause in approximately half of the 7000 RDs currently classified. As this technology
advances and the price continues to fall, we will soon be in a position to perform Whole Genome
Sequencing (WGS) as a standard research tool which will help realise the goals of groups such as the
International Rare Diseases Research Consortium (IRDiRC) of identifying the genetic cause of all RDs
by 2020.
Projects such as the 100,000 Genomes Project (100KGP) will provide a huge boost to the goals of
IRDiRC and lay the foundations of introducing genomics into the routine healthcare environment as
well as producing an unprecedented data source that will drive the implementation of higher order
analyses, such as network analyses to mine for novel disease genes and phenotypic modifiers. The
goal of such analyses is to lead to a better understanding of the underlying pathobiology which can
be modelled in cell or animal systems with the aim that armed with this knowledge we can develop
specific drugs or therapies that alleviate disease symptoms or even prevent them occurring at all. By
understanding how our genetic background can modify a disease phenotype we can begin to treat
patients on an individualised nature which is the goal of personalised medicine.
3. Expert commentary:
The field of Rare Disease research and diagnosis is being transformed through the use of Next
Generation Sequencing (NGS). In the research realm the falling cost of NGS, especially Whole
Genome Sequencing (WGS), is leading to a position where it will be the method of choice for most
groups within the next few years. This is has resulted in an ever increasing number of RD genes being
identified which is also driving the use of molecular techniques to functionally characterise these
genes. Concomitantly, in the diagnostic realm a point will be reached soon where WGS becomes the
preferred option as gene panels are growing to a point where it will be more efficient to perform
WGS and apply virtual gene panels. To this end, the 100,000 Genomes Project in the UK is set to
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revolutionise the implementation of genomics into healthcare and will set the standard practises
that will be the blueprint for countries around the world. For RD patients this will lead to improved
rates of diagnosis and with it the hope that it will drive innovation in the fields of drug discovery and
therapeutic interventions to allow the realisation of personalised medicines.
4. Five-year view:
The field of Next Generation Sequencing (NGS) is still relatively new, it has only been with us for
around 10 years and although its use is increasing it is still mainly restricted to specialised research
groups. In the field of Rare Disease (RD) research the use of NGS has led to the identification of a
huge number of novel genes and that number is increasing all the time. The increased use of NGS is
being driven by technological advances which result in ever falling costs and have reached the point
where we are almost at the ‘$1000 Genome’ threshold. These reduced costs have allowed projects
such as the 100,000 Genomes Project (100KGP) in the UK to be financially viable and through these
large scale endeavours the rate of novel gene discovery is set to increase drastically over the next 5
years. Importantly, the 100KGP will set a benchmark that can be followed by other groups because if
we want this data to be accessible to the whole community then standards have to be put in place
that make the data generated from different groups compatible. One of the main outputs of the
100KGP is likely to be the integration of Whole Genome Sequencing (WGS) data into a standard
healthcare system so that WGS moves away from being the reserve of research groups and becomes
a standard diagnostic clinical tool. The accumulation of the huge amounts of genome wide data on
hundreds of thousands humans from a range of populations will drive the innovation of higher
analytical techniques to mine the data and lead to a far greater understanding of human genetic
diversity.
5. Key issues:
 There are at least 7000 rare diseases with the causative gene identified in about half.
 Rarity of many diseases makes finding families to replicate candidate mutations difficult.
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 Many patients have unique phenotypes that make them intractable to standard diagnoses
which is a huge barrier to them receiving appropriate treatment.
 Next Generation Sequencing technologies have had a profound influence in the rare disease
field and the rate of novel genes being discovered is increasing massively.
 Being able to accurately phenotype patients in a standardised manner, using electronic
records is a necessity for the future.
 The decreasing cost of NGS, especially whole genome sequencing, is allowing projects such
as the 100,000 Genomes Project in the UK to be conducted which will revolutionise
healthcare in the future.
 The huge amounts of data being produced result in an unprecedented computational
burden and require solutions to allow the safe storage, analysis and interpretation of NGS
data.
 Higher order analytical techniques such as those employing bio-statistical algorithms,
machine learning techniques and network analyses will be required to mine the vast
amounts of data to find causative and modifying genes.
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